Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford spinout EvOx Therapeutics will harness the body's own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable – including those affecting the brain, as well as autoimmune diseases and cancers.

EvOx has raised £10m in seed funding from investment company Oxford Sciences Innovation to move the technology through pre-clinical and early clinical trials.

The Oxford team has been led by DPAG's Professor Matthew Wood and Dr Samir El Andaloussi, Research Fellow at Oxford and Assistant Professor at Sweden's Karolinska Institutet. They found that by using the body's own mini-transporters – tiny circular nanostructures which shuttle materials between cells – they are able to smuggle drug therapies into the brain, targeting new treatments to the correct tissues.

Read more here.

Similar stories

New research to radically alter our understanding of synaptic development

Publication Research

A new study from the Molnár group on the role of regulated synaptic vesicular release in specialised synapse formation has made it to the cover of Cerebral Cortex.

Being "in the zone": how waking activity controls sleep need

Publication Research Vyazovskiy Group News

A new study from the Vyazovskiy group suggests that how and where we spend our time while awake impacts how much we need to sleep - it does not only depend on how long we are awake.

New target identified to develop treatment for Abdominal Aortic Aneurysm

Cardiac Theme Publication Research

A new study from the Smart group has shed light on a key regulatory step in the initiation and progression of Abdominal Aortic Aneurysm by revealing the protective role of a previously little known small protein.

Drug trial that could improve respiratory recovery from COVID-19 now underway

Research

A clinical trial has commenced this week to test whether a drug called almitrine can help people who are seriously ill with COVID-19 to recover from the disease.

Same genome, different worlds: How a similar brain causes sexually dimorphic behaviours

CNCB Goodwin Group News Publication Research

A new paper from the Goodwin group based in DPAG's Centre for Neural Circuits and Behaviour has shown how males and females are programmed differently in terms of sex.